FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1808523312> ?p ?o ?g. }

• W1808523312 endingPage "e0138332" @default.
• W1808523312 startingPage "e0138332" @default.
• W1808523312 abstract "Background There exists a subpopulation of T2DM in whom first-line doses of statin are insufficient for optimally reducing LDL-C, representing a major risk of CVD. The RESEARCH study focuses on LDL-C reduction in this population along with modifications of the lipid profiles leading to residual risks. Methods Lipid changes were assessed in a randomized, multicenter, 12-week, open-label study comparing a high-potency statin (10mg of atorvastatin or 1mg of pitavastatin) plus ezetimibe (EAT: n = 53) with a double dose of statin (20mg of atorvastatin or 2mg of pitavastatin) (DST: n = 56) in DM subjects who had failed to achieve the optimal LDL-C targets. Lipid variables were compared with a primary focus on LDL-C and with secondary focuses on the percentage of patients who reached the LDL-C targets and changes in the levels of RLP-C (remnant like particle cholesterol) and sd-LDL-C, two characteristic atherogenic risks of DM. Results The reduction of LDL-C (%), the primary endpoint, differed significantly between the two groups (-24.6 in EAT vs. -10.9 in DST). In the analyses of the secondary endpoints, EAT treatment brought about significantly larger reductions in sd-LDL-C (-20.5 vs. -3.7) and RLP-C (-19.7 vs. +5.5). In total, 89.4% of the patients receiving EAT reached the optimized treatment goal compared to 51.0% of the patients receiving DST. The changes in TC (-16.3 vs. -6.3) and non-HDL-C (-20.7 vs. -8.3) differed significantly between the two groups. Conclusion Ezetimibe added to high-potency statin (10 mg of atorvastatin or 1 mg of pitavastatin) was more effective than the intensified-dose statin (20 mg of atorvastatin or 2 mg of pitavastatin) treatment not only in helping T2DM patients attain more LDL-C reduction, but also in improving their atherogenic lipid profiles, including their levels of sd-LDL-C and RLP-C. We thus recommend the addition of ezetimibe to high-potency statin as a first line strategy for T2DM patients with insufficient statin response. Trial Registration The UMIN Clinical Trials Registry UMIN000002593" @default.
• W1808523312 created "2016-06-24" @default.
• W1808523312 creator A5006982144 @default.
• W1808523312 creator A5008256037 @default.
• W1808523312 creator A5014958501 @default.
• W1808523312 creator A5021311208 @default.
• W1808523312 creator A5032266366 @default.
• W1808523312 creator A5036058113 @default.
• W1808523312 creator A5038634690 @default.
• W1808523312 creator A5048648363 @default.
• W1808523312 creator A5049404938 @default.
• W1808523312 creator A5056000099 @default.
• W1808523312 creator A5058670429 @default.
• W1808523312 creator A5058848395 @default.
• W1808523312 creator A5060288823 @default.
• W1808523312 creator A5061345986 @default.
• W1808523312 creator A5069254447 @default.
• W1808523312 creator A5073711245 @default.
• W1808523312 creator A5081422004 @default.
• W1808523312 creator A5084233240 @default.
• W1808523312 creator A5087133197 @default.
• W1808523312 date "2015-09-23" @default.
• W1808523312 modified "2023-10-16" @default.
• W1808523312 title "Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by Statins" @default.
• W1808523312 cites W138039351 @default.
• W1808523312 cites W1968630986 @default.
• W1808523312 cites W1969054950 @default.
• W1808523312 cites W1969534558 @default.
• W1808523312 cites W1972572769 @default.
• W1808523312 cites W1992085688 @default.
• W1808523312 cites W1996592745 @default.
• W1808523312 cites W2007221722 @default.
• W1808523312 cites W2019071303 @default.
• W1808523312 cites W2020158846 @default.
• W1808523312 cites W2020947054 @default.
• W1808523312 cites W2021976026 @default.
• W1808523312 cites W2025690892 @default.
• W1808523312 cites W2050758709 @default.
• W1808523312 cites W2053365438 @default.
• W1808523312 cites W2064344939 @default.
• W1808523312 cites W2066894557 @default.
• W1808523312 cites W2072946847 @default.
• W1808523312 cites W2076649281 @default.
• W1808523312 cites W2083734048 @default.
• W1808523312 cites W2085942677 @default.
• W1808523312 cites W2089103283 @default.
• W1808523312 cites W2089283085 @default.
• W1808523312 cites W2091031663 @default.
• W1808523312 cites W2091709412 @default.
• W1808523312 cites W2097192292 @default.
• W1808523312 cites W2097870088 @default.
• W1808523312 cites W2098774809 @default.
• W1808523312 cites W2108169164 @default.
• W1808523312 cites W2109020055 @default.
• W1808523312 cites W2109806543 @default.
• W1808523312 cites W2111186986 @default.
• W1808523312 cites W2113213810 @default.
• W1808523312 cites W2124186024 @default.
• W1808523312 cites W2127626398 @default.
• W1808523312 cites W2130581440 @default.
• W1808523312 cites W2132840845 @default.
• W1808523312 cites W2134120087 @default.
• W1808523312 cites W2142478583 @default.
• W1808523312 cites W2162430779 @default.
• W1808523312 cites W2167045683 @default.
• W1808523312 cites W2247997571 @default.
• W1808523312 cites W2323976047 @default.
• W1808523312 cites W2475261460 @default.
• W1808523312 cites W2607031541 @default.
• W1808523312 cites W3171237122 @default.
• W1808523312 cites W35016999 @default.
• W1808523312 cites W4211109054 @default.
• W1808523312 cites W4238251256 @default.
• W1808523312 cites W4292114749 @default.
• W1808523312 cites W4367363114 @default.
• W1808523312 doi "https://doi.org/10.1371/journal.pone.0138332" @default.
• W1808523312 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4580589" @default.
• W1808523312 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26398887" @default.
• W1808523312 hasPublicationYear "2015" @default.
• W1808523312 type Work @default.
• W1808523312 sameAs 1808523312 @default.
• W1808523312 citedByCount "23" @default.
• W1808523312 countsByYear W18085233122016 @default.
• W1808523312 countsByYear W18085233122017 @default.
• W1808523312 countsByYear W18085233122018 @default.
• W1808523312 countsByYear W18085233122019 @default.
• W1808523312 countsByYear W18085233122020 @default.
• W1808523312 countsByYear W18085233122022 @default.
• W1808523312 countsByYear W18085233122023 @default.
• W1808523312 crossrefType "journal-article" @default.
• W1808523312 hasAuthorship W1808523312A5006982144 @default.
• W1808523312 hasAuthorship W1808523312A5008256037 @default.
• W1808523312 hasAuthorship W1808523312A5014958501 @default.
• W1808523312 hasAuthorship W1808523312A5021311208 @default.
• W1808523312 hasAuthorship W1808523312A5032266366 @default.
• W1808523312 hasAuthorship W1808523312A5036058113 @default.
• W1808523312 hasAuthorship W1808523312A5038634690 @default.
• W1808523312 hasAuthorship W1808523312A5048648363 @default.

• next